结核分枝杆菌耐喹诺酮临床分离株gyrA基因突变的研究

摘要/Abstract

摘要： 目的　了解结核分枝杆菌喹诺酮 (quinolones)耐药株耐药基因突变情况,评价其应用价值。方法通过 16SrRNA聚合酶链反应-单链构象多态性 (PCR SSCP)技术分析 77株分枝杆菌临床分离株；通过PCR SSCP和直接测序技术分析结核分枝杆菌的gyrA基因突变的情况。结果 75株为结核分枝杆菌复合群。 30株喹诺酮敏感株的 gyrA基因的SSCP图谱中,11株与H₃₇R_v相同,19株与卡介苗相同；与卡介苗 gyrA基因的SSCP图谱相同的敏感株 95位密码子为ACC,与H₃₇R_v该图谱相同的敏感株 95位密码子为AGC。 45株喹诺酮耐药株中,34株 (75.6%) gyrA基因SSCP图谱泳动异常,对 25株泳动异常、出现频率较高耐药株测序证实 15株 (44.1%)为 94位密码子GAC→GGC突变；10株 (29.4%)为 90位密码子GCG→GTG的突变。结论结核分枝杆菌耐喹诺酮与 gyrA基因突变有关,PCR SSCP可能成为测定结核分枝杆菌耐喹诺酮类药基因型的快速、简便的方法。

关键词: 分枝杆菌,结核, 喹诺酮, 药物耐受性, 聚合酶链反应, 多态性,单链构象

Abstract: Objective To observe the mutations of gyrA gene in M.Tuberculosis quinolones-resistant isolates,and to evaluate their clinical value.Methods 77 clinical isolates were identified for their mycobacteria species,and were analyzed M.tuberculosis gyrA genes by PCR-SSCP and PCR-direct sequencing.Results Seventy-five isolates were identified as M.tuberculosis.Of 30 quinolones-sensitive isolates,11 isolates had same gyrA SSCP profiles as H₃₇R_v,19 had same profiles as M.bovis BCG.The drug-sensitive isolates whose gyrA SSCP profiles was identical to H₃₇R_v were AGC at condon 95,the others were ACC at condon 95.Of 45 quinolones-resistant isolates,34 (75.6%) displayed abnormal gyrA SSCP profiles.25 clinicals of 2 kinds of gyrA SSCP profiles which appeared at a high frequency were sequenced.15 isolates had GAC→GGC mutation at condon 94;10 isolates had GCG→GTG mutation at condon 90.Conclusion Quinolones resistances in some M.tuberculosis isolates were due to mutation on gyrA genes.PCR-SSCP method might become a simple and rapid diagnostic test for identification of genotypes of M.tuberculosis quinolones-resistance.

Key words: Mycobacterium tuberculosis, Quinolones, Drug-resistance, Polymerase chain reaction, Polymorphism,single-stranded conformational

安慧茹,王巍,李洪敏,梁建琴,刘真,李素梅,何珂,. 结核分枝杆菌耐喹诺酮临床分离株gyrA基因突变的研究[J]. 中国防痨杂志, 2004, 26(3): 129-132.

An Huiru,Wang Wei,Li Hongmin,et al.. Study on gyrA mutation in Mycobacterium tuberculosis quinolone-resistant isolates[J]. Chinese Journal of Antituberculosis, 2004, 26(3): 129-132.

参考文献

1 Ouabdesselam S, Hooper D C, Tankovic J, et al.Detection of gyrA and gyrB mutations in quinolone-resistant ctinical isolates of Escherichia coli by single-strand conformation polymorphism analysis and determination of levels of resistance conferred by two different single gyrA mutations.Antimicrob Agents Chemother [J].1995,39(8)：1667～1670.
2 郑东钧，宋诗铎,祁伟,等.临床分离耐氟喹诺酮金黄色葡萄球菌的耐药机制研究[J].中华传染病杂志，1997,15:130～133.
3 吴雪琼、张俊仙、刘佳文等.PCR-SSCP分枝杆菌菌种初步鉴定方法的建立及其应用[J].中国现代医学杂志,2000，10(7):25～26.
4 Takiff H E, Salazar L, Guerrero C, et al. Cloning and nucleotide sequence of Mycobacterium tuberculosis gyrA and gyrB genes and detection of quinolone resistance mutations[J]. Antimicro Agents Chemother, 1994,38(4)：773～780.
5 Guillemin I, Cambau E and Jarlier V.Sequences of conserved region in the A subunit of DNA Gyrase from Nine Species of the Genus Mycobacterium: Phylogenetic analysis and implication for inrinsic susceptibility to quinolones[J]. Antimicrobial agents and chemotherapy,1995,39(9):2145～2149.
6 George J, Manavathu E K, Vakulenko,SB,et al. Characterization of fluoroquinolone-resistant mutant strains of mycobacterium tuberculosis selected in the laboratory and isolated from patients [J].Antimicrobial agents and chemotherapy.1995,39(8):1700～1703.
7 Kocagoz T, Hackbarth C, Unsal Z,et al. Gyrase mutations in laboratory-selected, fluoroquinolone-resistant, mutants of mycobacterium tuberculosis H₃₇R_a [J]. Antimicrobial agents and chemotherapy,1996,46(8):1768～1774.
8 Onodera Y, Tanaka M and Sato K. Inhibitory activity of quinolones against DNA gyrase of Mycobacterium tuberculosis[J]. Journal of Antimicrobial Chemot herapy,2001,47:447～450.
9 Jarlier V, and Nikaido H. Permeability barrier to hydrophilic solutes in Mycobacterium chelonei[J]. J Bacteriol,1990,172：1418～1423.
10 Takiff H E, Cimino M, Musso M C,et al. Efflux pump of the proton antiporter family confers low-level fluoroquinolone resistance in Mycobacterium smegmatis[J]. Proc. Natl. Acad. Sci. USA,1996，93:362～366.

[1]	李爱芳, 崔晓利, 康磊, 雷静, 党丽云, 杨翰. 荧光PCR探针熔解曲线法检测结核分枝杆菌耐药性的价值[J]. 中国防痨杂志, 2020, 42(9): 998-1001.
[2]	张静, 陈曦, 王彬, 付雷, 陆宇, 陈效友. 改良单叠氮丙啶-荧光定量PCR法的建立及其检测抗结核药物活性的价值[J]. 中国防痨杂志, 2020, 42(5): 472-480.
[3]	周银发,张山鹰,戴志松,陈代权,李卫林,赵永,林淑芳. 福建省耐药肺结核高危人群利福平耐药情况及其影响因素分析[J]. 中国防痨杂志, 2020, 42(4): 339-344.
[4]	张蓝月,耿艺漫,贾红彦,肖婧,李自慧,潘丽萍,孙义成,张宗德. 耻垢分枝杆菌新型毒素-抗毒素系统MSMEG_3435-3436基因功能的初步研究[J]. 中国防痨杂志, 2020, 42(2): 133-142.
[5]	于佳佳, 张旭霞, 张雨晴, 任卫聪, 姚丛, 李传友, 刘毅, 唐神结. PCR扩增技术联合CRISPR-Cas13a系统对MTB DNA检测方法的初步研究[J]. 中国防痨杂志, 2020, 42(12): 1280-1288.
[6]	吕纯芳,吴健虹,卢留珠,徐阳凤,刘盛元. 国产实时荧光定量PCR试剂与GeneXpert MTB/RIF检测结核分枝杆菌的对比分析[J]. 中国防痨杂志, 2020, 42(1): 60-65.
[7]	曹志华,赵悦竹,胡双双. 荧光 PCR 探针熔解曲线技术检测结核分枝杆菌对五种抗结核药物耐药性的研究[J]. 中国防痨杂志, 2019, 41(2): 156-161.
[8]	吴慧娜,孙付胜,刘清文,戎中录,张纪东,高阳,李永福,常斐. 荧光PCR探针熔解曲线法检测结核分枝杆菌复合群对利福平和异烟肼耐药性的价值[J]. 中国防痨杂志, 2019, 41(1): 74-79.
[9]	程丽平,张晓岩,沙巍. 痰标本PCR-反向斑点杂交法对疑似非结核分枝杆菌肺病的诊断价值[J]. 中国防痨杂志, 2018, 40(8): 834-839.
[10]	董宇杰,张莉,王宇轩,周立娟,曲杨,张晨,张海青,车南颖. 免疫组织化学及PCR技术在淋巴结结核病理诊断中的应用价值[J]. 中国防痨杂志, 2018, 40(4): 348-352.
[11]	郭俊红,武春燕,董正伟,吴伟,张莉萍,李辉,黄焰. CT引导下肺穿刺活检标本行PCR检测诊断肺结核的临床价值[J]. 中国防痨杂志, 2018, 40(11): 1159-1163.
[12]	胡彦,刘洁,沈静,朱大冕,冯鑫,陈林,詹建,欧喜超,周杨,赵雁林. 重庆地区耐多药结核分枝杆菌对氟喹诺酮类药物耐药的相关基因特征分析[J]. 中国防痨杂志, 2018, 40(10): 1060-1065.
[13]	吴雪琼张俊仙. 合理应用药物敏感性试验提高耐多药结核病诊断率[J]. 中国防痨杂志, 2017, 39(3): 222-225.
[14]	程丽平，肖和平. 三种检测方法联合使用对结核性胸膜炎的诊断价值[J]. 中国防痨杂志, 2016, 38(11): 956-962.
[15]	杜鹃，田丹，陈国玺，姚芳，陈俊，兰星，袁保东. 初治涂阳肺结核患者采用含氟喹诺酮类药物治疗方案的疗效分析[J]. 中国防痨杂志, 2016, 38(11): 968-972.